Published
AstraZeneca’s ambitious vaccine dreams are finally, officially dead
One major caveat: even if the bill passes, it would be up to the FDA to decide when to crack down — and not everyone is convinced they will. “I’m, for one, a bit skeptical that this would immediately change [things] too much, unless, of course, the FDA completely shifted its enforcement posture,” said Jonathan Havens, an attorney that represents CBD makers.
Related Professional
